Iohexol
Based on 5 publication(s) in Google Scholar
Iohexol is a non-ionic, water-soluble contrast agent used as a reference marker for the determination of glomerular filtration rate (GFR) at the level of renal function. Iohexol can be used for contrast in myelography, computerized tomography (cisternography, ventriculography) and MicroCT imaging.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.54%
- CAS No.: 66108-95-0
- 화학식: C19H26I3N3O9
- 분자량:821.14
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Mitochondria-Targeted Compound Library
HY-L089
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Cell Death Library
HY-L162
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Cardiotoxic Compound Library
HY-L225
Publications Citing Use of MedChemExpress (MCE) Iohexol
More
Customer Validation & Images
-
Flow Cytometry
-
Cell Migration/Invasion Assay
-
Cell Imaging/Staining
-
Histological Imaging/Staining
-
Histological Imaging/Staining
Biological Activity
Iohexol (150 mg I/mL, 0-24 h) inhibits the cell viability of NRK 52-E[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NRK 52-E
-
Concentration:150 mg I/mL
-
Incubation Time:0-24 h
-
Result:Reduced the MTT conversion at 12 and 24 h.
Inhibited mitochondrial dehydrogenase activity at 12 and 24 h.
Iohexol (64.7 mg/kg, i.v.) can be used to evaluate glomerular filtration rate (GFR) in healthy or dogs with presenting chronic kidney disease (CKD)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Healthy dogs [4]
-
Dosage:0.25-4 mL/kg
-
Administration:Oral gavage (p.o.), weekly
-
Result:Peaked the iohexol serum concentrations between 2 and 4 hours.
Reduced radiolucency after application of 0.25 mL/kg and 4 mL/kg.
Included watery diarrhea after ingestion of 4 mL/kg.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 66108-95-0
-
Appearance Solid
-
분자량 821.14
-
화학식 C19H26I3N3O9
-
Color White to off-white
-
SMILES
O=C(C1=C(I)C(N(C(C)=O)CC(O)CO)=C(I)C(C(NCC(O)CO)=O)=C1I)NCC(O)CO
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Iodine nanoparticles enhance radiotherapy of intracerebral human glioma in mice and increase efficacy of chemotherapy. [Abstract]2019 Mar 14;9(1):4505. PMID: 30872755 -
Sci Rep
2018 Sep 14;8(1):13803. PMID: 30218059
Iohexol purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Sep 14;8(1):13803. [Abstract]
At 2 minutes post-injection, the widely used iodine contrast agent iohexol had accumulated in the kidneys while INPs continued to opacify renal vasculature.
Iohexol purchased from MedChemExpress. Usage Cited in: Sci Rep. 2018 Sep 14;8(1):13803. [Abstract]
MicroCT coronal views of mouse 30 min after IV injection of INP or Iohexol (Both with 1.75 g I/kg IV injection). Vascularization is clearly seen at this time with the INPs.
-
IUBMB Life
2025 May;77(5):e70022. PMID: 40391788 -
BMC Nephrol
Sodium selenite attenuates inflammatory response and oxidative stress injury by regulating the Nrf2/ARE pathway in contrast-induced acute kidney injury in rats. [Abstract]2024 Jul 15;25(1):226. PMID: 39009991 -
Physiol Res
The Role of Mdivi-1 in Reducing Mitochondrial Fission via the NF-kappaB/JNK/SIRT3 Signaling Pathway in Acute Kidney Injury. [Abstract]2025 Mar 24;74(1):79-92. PMID: 40126145
Iohexol purchased from MedChemExpress. Usage Cited in: Physiol Res. 2025 Mar 24;74(1):79-92. [Abstract]
Flow cytometry results in control, Iohexol (100 mgI/mL), Genta, or Cisplatin group.
Iohexol purchased from MedChemExpress. Usage Cited in: Physiol Res. 2025 Mar 24;74(1):79-92. [Abstract]
Migration ability of HK-2 cells in each group. Cell growth photographed under a microscope after culture for 24 h and 48 h in control, Iohexol, Genta, or Cisplatin group; value of migration rate.
Iohexol purchased from MedChemExpress. Usage Cited in: Physiol Res. 2025 Mar 24;74(1):79-92. [Abstract]
Expression of ROS in HK-2 cells in each group. Laser confocal microscopy photograph in control, Iohexol-3 (administered 3 μM of Mdivi-1), Iohexol, Genta-1 (treated with 1 μM of Mdivi-1), Genta, Cisplatin-5 (treated with 5 μM of Mdivi-1), or Cisplatin group; ROS level in each group.
용액&용해도
H2O : ≥ 50 mg/mL (60.89 mM)
DMSO : 50 mg/mL (60.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 120 mg/mL (146.14 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
순도&문서
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Soman RS, et al. Development and validation of an HPLC-UV method for determination of iohexol in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 25;816(1-2):339-43. [Content Brief]
[2]. Hainfeld JF, Ridwan SM, Stanishevskiy Y, Smilowitz NR, Davis J, Smilowitz HM. Small, Long Blood Half-Life Iodine Nanoparticle for Vascular and Tumor Imaging. Sci Rep. 2018 Sep 14;8(1):13803. [Content Brief]
[3]. Jensen H, et al. The effects of the iodinated X-ray contrast media iodixanol, iohexol, iopromide, and ioversol on the rat kidney epithelial cell line NRK 52-E. Ren Fail. 2011;33(4):426-33. [Content Brief]
[4]. Klenner S, et al. Estimation of intestinal permeability in healthy dogs using the contrast medium iohexol. Vet Clin Pathol. 2009 Sep;38(3):353-60. [Content Brief]
[5]. Baklouti S, et al. Population Pharmacokinetic Model of Iohexol in Dogs to Estimate Glomerular Filtration Rate and Optimize Sampling Time. Front Pharmacol. 2021 Apr 29;12:634404. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 1.2178 mL | 6.0891 mL | 12.1782 mL | 30.4455 mL |
| 5 mM | 0.2436 mL | 1.2178 mL | 2.4356 mL | 6.0891 mL | |
| 10 mM | 0.1218 mL | 0.6089 mL | 1.2178 mL | 3.0445 mL | |
| 15 mM | 0.0812 mL | 0.4059 mL | 0.8119 mL | 2.0297 mL | |
| 20 mM | 0.0609 mL | 0.3045 mL | 0.6089 mL | 1.5223 mL | |
| 25 mM | 0.0487 mL | 0.2436 mL | 0.4871 mL | 1.2178 mL | |
| 30 mM | 0.0406 mL | 0.2030 mL | 0.4059 mL | 1.0148 mL | |
| 40 mM | 0.0304 mL | 0.1522 mL | 0.3045 mL | 0.7611 mL | |
| 50 mM | 0.0244 mL | 0.1218 mL | 0.2436 mL | 0.6089 mL | |
| 60 mM | 0.0203 mL | 0.1015 mL | 0.2030 mL | 0.5074 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Iohexol Related Classifications
HY-B0594 Related Classifications
Powered by Bioz